Wiley & Sons has published a peer-reviewed review cataloging emerging RNA-interference pesticide platforms. The paper, "RNAi-Based Pesticides: Genetic Innovations for Sustainable Crop Protection and One Health," frames dsRNA gene-silencing as the next genetic frontier for sustainable crop protection.

The publication enters agribusiness literature as synthetic-chemistry input costs climb and resistance pressure builds against major mode-of-action groups. RNAi operates differently from conventional chemistries. Double-stranded RNA molecules silence specific genes in target pests by triggering the organism's own RNA-interference pathway. Non-target species remain largely unaffected. The compounds break down quickly in soil and water.

Why does One Health framing matter here?

The review couples RNAi pesticides with One Health, the cross-sector framework linking animal, human, and environmental health outcomes. Crop pesticide decisions draw increasing scrutiny, particularly for chemistries with documented residue or pollinator exposure concerns. RNAi's mode of action and rapid environmental degradation position it as a candidate that satisfies sustainability benchmarks downstream buyers now require.

Buyer-side pressure shapes the calculus. EU residue thresholds and corporate sustainability commitments from food manufacturers increasingly influence crop input choices at the farm gate. Growers adopting RNAi-aligned practices may capture value through premium contracts and residue-low certifications.

Agricultural economists will watch the platform's cost trajectory. Transgenic seed-delivered RNAi traits carry biotech seed premiums and refuge requirements. Spray-applied RNAi candidates, still largely in research pipelines, could lower entry costs for non-GM cropping systems if stability and field-efficacy hurdles clear.

What regulatory pathways apply?

Regulatory pathways differ sharply by delivery mode. Transgenic RNAi traits fall under USDA-APHIS biotechnology oversight and EPA pesticide registration. Spray-applied dsRNA products may proceed under EPA conventional pesticide review, depending on formulation. Global regulators draft gene-silencing guidance as the technology matures.

The review arrives as EPA, EFSA, and other agencies confront a growing sprayable-RNAi docket. Field-trial data on degradation half-life, non-target effects, and resistance-management strategy will determine commercial timelines. Sprayable dsRNA products may face additional delay as agencies establish baseline protocols for gene-silencing active ingredients not previously reviewed.

Where does resistance management fit?

Resistance-management protocols will shape RNAi adoption curves. Pest populations can evolve insensitivity to dsRNA through upregulation of dsRNA-degrading enzymes or suppression of core RNAi pathways. Industry stewardship programs in biotech crops provide a template for RNAi management. The review's One Health framing suggests coordinated protocols across cropping systems.

For input manufacturers, the platform opens chemistry-independent revenue lines but adds manufacturing complexity. Long dsRNA synthesis at agricultural volumes remains capital-intensive. Process improvements, microbial expression systems, and formulation chemistry will dictate unit economics. Cooperatives and ag retailers should track registration milestones closely, as RNAi traits and sprays will require updated agronomic recommendations and integrated pest management protocols.

What does this mean for growers and input makers?

Expect follow-up field data as university and corporate pipelines advance spray-applied candidates toward registration. The Wiley review establishes a research baseline that crop protection firms, regulatory agencies, and grower cooperatives can reference as gene-silencing products approach commercial release.